Trends of 5-Aminosalicylate Medication Use in Patients With Crohn Disease
- 29 May 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 27 (4), 516-521
- https://doi.org/10.1093/ibd/izaa127
Abstract
5-aminosalicylate (5-ASA) medications have a long history of use for the treatment of inflammatory bowel disease and continue to be widely prescribed today. The effectiveness of 5-ASAs in ulcerative colitis is clear; however, studies have shown little benefit for induction or maintenance treatment of Crohn disease (CD). We aimed to quantify usage and examine trends in 5-ASA prescription rates in patients with CD. Using a retrospective design, we queried a national database of commercially insured patients (Truven-Health databases) between 2009 and 2014 to identify patients with CD aged 18 to 65 years. Prescription rates for 5-ASA medications including sulfasalazine, mesalamine, olsalazine, and balsalazide were calculated for each calendar year. Regression models were used to examine year-to-year trends in prescription rates and identify patient factors associated with 5-ASA use. We identified 132,804 patients with CD, of whom 37.3% (n = 49,529) received a 5-ASA prescription during the study period. From 2009 to 2014, the overall prescription rates of 5-ASAs declined from 42.9% to 30.0% (P < 0.001). Patient factors independently associated with 5-ASA use included younger age, male sex, multimorbidity, and a health maintenance organization insurance plan, while controlling for the region of residence. About 1 in 3 privately insured patients with CD received 5-ASA prescriptions despite their questionable effectiveness; however, in an encouraging trend, prescription rates significantly decreased from 2009 to 2014. This high prescription rate may reflect a gap in providers’ knowledge regarding the available evidence—an opportunity for cost savings with improved health care delivery.Keywords
Funding Information
- NIH
This publication has 27 references indexed in Scilit:
- Management of Crohn's disease – are guidelines transferred to clinical practice?United European Gastroenterology Journal, 2015
- The answer is 17 years, what is the question: understanding time lags in translational researchJournal of the Royal Society of Medicine, 2011
- Preparing for biologic or immunosuppressant therapy.2011
- Diffusion Theory and Knowledge Dissemination, Utilization, and Integration in Public HealthAnnual Review of Public Health, 2009
- 5-Aminosalicylic acid (mesalazine) use in Crohnʼs disease: A survey of the opinions and practice of Australian gastroenterologistsInflammatory Bowel Diseases, 2007
- Bridging the gap between research and practice: a continuing challengeInjury Prevention, 2006
- Oral pentasa in the treatment of active Crohn?s disease: A meta-analysis of double-blind, placebo-controlled trialsClinical Gastroenterology and Hepatology, 2004
- Closing the gap between nursing research and practiceEvidence-Based Nursing, 1998
- Mesalamine capsules for the treatment of active Crohn's disease: Results of a 16-week trialGastroenterology, 1993
- Sulphasalazine and Prednisone Compared with Sulphasalazine for Treating Active Crohn DiseaseAnnals of Internal Medicine, 1991